You're describing a chemical compound with a rather complex name. Let's break it down:
**1-(4-morpholinyl)-2-[2-(phenylmethylthio)-1-benzimidazolyl]ethanone**
* **1-(4-morpholinyl):** This indicates a morpholine ring (a six-membered ring containing oxygen and nitrogen) attached at the 1-position of the molecule.
* **2-[2-(phenylmethylthio)-1-benzimidazolyl]ethanone:** This is a more complex part.
* **2-benzimidazolyl:** This indicates a benzimidazole ring (a fused ring system with a benzene ring and an imidazole ring) attached at the 2-position.
* **1-benzimidazolyl:** This further specifies that the benzimidazole ring is attached at its 1-position.
* **2-(phenylmethylthio):** This means a phenylmethyl (benzyl) group is attached at the 2-position of the benzimidazole ring, with a sulfur atom (thio) connecting them.
* **ethanone:** This means a ketone group (C=O) is attached to the molecule, specifically at the 2-position.
**Overall Structure:** The molecule is likely a derivative of benzimidazole with a morpholine group, a benzylthio group, and a ketone function.
**Importance in Research:**
Given the complexity of the compound, it's likely to be a synthetic organic compound created for research purposes. Here's why this type of molecule could be of interest:
* **Pharmacology:** Benzimidazole derivatives are known for their biological activity. They've been used in various drugs, including antiparasitic agents, antiulcer drugs, and anticancer agents. The specific combination of functional groups in this molecule could be explored for its potential to interact with biological targets.
* **Materials Science:** The presence of the sulfur atom could indicate potential use in materials science. Sulfur-containing compounds can be used to create conductive polymers, photochromic materials, and other interesting materials.
* **Synthesis:** The molecule itself might be a precursor for other complex compounds, making it useful in synthetic chemistry research.
**To know more about its specific importance, you would need:**
* **Context:** Where did you encounter this compound (research paper, patent, etc.)?
* **Research Aim:** What was the specific research goal for which this compound was synthesized or studied?
If you provide more information, I can provide a more specific answer regarding its importance.
ID Source | ID |
---|---|
PubMed CID | 1089009 |
CHEMBL ID | 1595703 |
CHEBI ID | 121809 |
Synonym |
---|
smr000122493 |
MLS000067937 , |
2-(2-benzylsulfanyl-benzoimidazol-1-yl)-1-morpholin-4-yl-ethanone |
CHEBI:121809 |
2-(2-benzylsulfanylbenzimidazol-1-yl)-1-morpholin-4-ylethanone |
2-[2-(benzylsulfanyl)-1h-1,3-benzodiazol-1-yl]-1-(morpholin-4-yl)ethan-1-one |
mfcd03942465 |
AKOS001682449 |
HMS2355G19 |
CHEMBL1595703 |
bdbm53732 |
1-morpholin-4-yl-2-[2-(phenylmethylsulfanyl)benzimidazol-1-yl]ethanone |
cid_1089009 |
2-[2-(benzylthio)benzimidazol-1-yl]-1-morpholino-ethanone |
1-(4-morpholinyl)-2-[2-(phenylmethylthio)-1-benzimidazolyl]ethanone |
Q27210381 |
Class | Description |
---|---|
benzimidazoles | An organic heterocyclic compound containing a benzene ring fused to an imidazole ring. |
[compound class information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res] |
Protein | Taxonomy | Measurement | Average (µ) | Min (ref.) | Avg (ref.) | Max (ref.) | Bioassay(s) |
---|---|---|---|---|---|---|---|
Luciferase | Photinus pyralis (common eastern firefly) | Potency | 26.8545 | 0.0072 | 15.7588 | 89.3584 | AID588342 |
ATAD5 protein, partial | Homo sapiens (human) | Potency | 12.9953 | 0.0041 | 10.8903 | 31.5287 | AID504467 |
Smad3 | Homo sapiens (human) | Potency | 12.5893 | 0.0052 | 7.8098 | 29.0929 | AID588855 |
nuclear receptor ROR-gamma isoform 1 | Mus musculus (house mouse) | Potency | 10.0000 | 0.0079 | 8.2332 | 1,122.0200 | AID2551 |
Guanine nucleotide-binding protein G | Homo sapiens (human) | Potency | 3.5481 | 1.9953 | 25.5327 | 50.1187 | AID624287 |
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023] |
Protein | Taxonomy | Measurement | Average | Min (ref.) | Avg (ref.) | Max (ref.) | Bioassay(s) |
---|---|---|---|---|---|---|---|
M1-family alanyl aminopeptidase | Plasmodium falciparum 3D7 | IC50 (µMol) | 48.6600 | 2.6000 | 48.1803 | 128.9800 | AID1445 |
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023] |
Process | via Protein(s) | Taxonomy |
---|---|---|
negative regulation of inflammatory response to antigenic stimulus | Guanine nucleotide-binding protein G | Homo sapiens (human) |
renal water homeostasis | Guanine nucleotide-binding protein G | Homo sapiens (human) |
G protein-coupled receptor signaling pathway | Guanine nucleotide-binding protein G | Homo sapiens (human) |
regulation of insulin secretion | Guanine nucleotide-binding protein G | Homo sapiens (human) |
cellular response to glucagon stimulus | Guanine nucleotide-binding protein G | Homo sapiens (human) |
[Information is prepared from geneontology information from the June-17-2024 release] |
Process | via Protein(s) | Taxonomy |
---|---|---|
G protein activity | Guanine nucleotide-binding protein G | Homo sapiens (human) |
adenylate cyclase activator activity | Guanine nucleotide-binding protein G | Homo sapiens (human) |
[Information is prepared from geneontology information from the June-17-2024 release] |
Process | via Protein(s) | Taxonomy |
---|---|---|
plasma membrane | Guanine nucleotide-binding protein G | Homo sapiens (human) |
[Information is prepared from geneontology information from the June-17-2024 release] |
Assay ID | Title | Year | Journal | Article |
---|---|---|---|---|
AID1745845 | Primary qHTS for Inhibitors of ATXN expression | |||
AID588499 | High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, MLPCN compound set | 2010 | Current protocols in cytometry, Oct, Volume: Chapter 13 | Microsphere-based flow cytometry protease assays for use in protease activity detection and high-throughput screening. |
AID588499 | High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, MLPCN compound set | 2006 | Cytometry. Part A : the journal of the International Society for Analytical Cytology, May, Volume: 69, Issue:5 | Microsphere-based protease assays and screening application for lethal factor and factor Xa. |
AID588499 | High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, MLPCN compound set | 2010 | Assay and drug development technologies, Feb, Volume: 8, Issue:1 | High-throughput multiplex flow cytometry screening for botulinum neurotoxin type a light chain protease inhibitors. |
AID588497 | High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, MLPCN compound set | 2010 | Current protocols in cytometry, Oct, Volume: Chapter 13 | Microsphere-based flow cytometry protease assays for use in protease activity detection and high-throughput screening. |
AID588497 | High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, MLPCN compound set | 2006 | Cytometry. Part A : the journal of the International Society for Analytical Cytology, May, Volume: 69, Issue:5 | Microsphere-based protease assays and screening application for lethal factor and factor Xa. |
AID588497 | High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, MLPCN compound set | 2010 | Assay and drug development technologies, Feb, Volume: 8, Issue:1 | High-throughput multiplex flow cytometry screening for botulinum neurotoxin type a light chain protease inhibitors. |
AID651635 | Viability Counterscreen for Primary qHTS for Inhibitors of ATXN expression | |||
AID588501 | High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, MLPCN compound set | 2010 | Current protocols in cytometry, Oct, Volume: Chapter 13 | Microsphere-based flow cytometry protease assays for use in protease activity detection and high-throughput screening. |
AID588501 | High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, MLPCN compound set | 2006 | Cytometry. Part A : the journal of the International Society for Analytical Cytology, May, Volume: 69, Issue:5 | Microsphere-based protease assays and screening application for lethal factor and factor Xa. |
AID588501 | High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, MLPCN compound set | 2010 | Assay and drug development technologies, Feb, Volume: 8, Issue:1 | High-throughput multiplex flow cytometry screening for botulinum neurotoxin type a light chain protease inhibitors. |
AID504810 | Antagonists of the Thyroid Stimulating Hormone Receptor: HTS campaign | 2010 | Endocrinology, Jul, Volume: 151, Issue:7 | A small molecule inverse agonist for the human thyroid-stimulating hormone receptor. |
AID504812 | Inverse Agonists of the Thyroid Stimulating Hormone Receptor: HTS campaign | 2010 | Endocrinology, Jul, Volume: 151, Issue:7 | A small molecule inverse agonist for the human thyroid-stimulating hormone receptor. |
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023] |
Timeframe | Studies, This Drug (%) | All Drugs % |
---|---|---|
pre-1990 | 0 (0.00) | 18.7374 |
1990's | 0 (0.00) | 18.2507 |
2000's | 1 (20.00) | 29.6817 |
2010's | 3 (60.00) | 24.3611 |
2020's | 1 (20.00) | 2.80 |
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] |
According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be weak demand-to-supply ratio for research on this compound.
| This Compound (12.56) All Compounds (24.57) |
Publication Type | This drug (%) | All Drugs (%) |
---|---|---|
Trials | 0 (0.00%) | 5.53% |
Reviews | 0 (0.00%) | 6.00% |
Case Studies | 0 (0.00%) | 4.05% |
Observational | 0 (0.00%) | 0.25% |
Other | 5 (100.00%) | 84.16% |
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] |